Dr Reddy's launches drug for stroke management

Dr Reddy's Laboratories Limited today announced the launch of Somazina, an innovator brand of Citicoline in the Indian market. The drug is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infraction, or who have undergone a brain surgery or have suffered from head injuries.

Dr Reddy's has partnered with the global innovator of Citicoline, Ferrer International S A of Spain to make Somazina available in India. "This is an important product in the management of stroke and has been used for treatment of post-stroke patients around the world," the company said.

Cerebral stroke is the third leading cause of deaths in India as each year 1.5 million people suffer from this medical emergency here."Citicoline is safe to use and may have a beneficial effect in stroke patients," it said.

"...With the launch of Somazina and our recent acquisition of Nootropil, through the UCB brand's acquisition, we look forward to building our presence in the Neurology segment and making a difference to the lives of patients who have had the misfortune to suffer a stroke," Alok Sonig, senior vice president of Dr Reddy's said in a press release.